# Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

> **NCT04608409** · PHASE1 · COMPLETED · sponsor: **Frederick R. Ueland, M.D.** · enrollment: 16 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Lapatinib and Paclitaxel

## Key facts

- **NCT ID:** NCT04608409
- **Lead sponsor:** Frederick R. Ueland, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-17
- **Primary completion:** 2024-05-17
- **Final completion:** 2024-05-17
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04608409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04608409, "Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04608409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*